Why I’d buy this investment trust ahead of Woodford Patient Capital

G A Chester explains why he’d avoid Woodford Patient Capital Trust plc (LON:WPCT) and buy this alternative instead.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’ve been highly critical of Neil Woodford’s Patient Capital Trust (LSE: WPCT) over the last couple of years. Here, I’ll explain why I’m continuing to avoid it, despite the board having recently reined Woodford in on gearing and new investments.

By contrast, I’d be happy to buy Caledonia Investments (LSE: CLDN), one of whose strategies also deploys so-called ‘patient capital’ — that’s to say, capital invested on a longer time horizon, with intensive support of management of the investee company, in anticipation of an ultimately higher return.

Concerns

My biggest concern about Patient Capital Trust has been its rapid morphing into a far riskier investment proposition than that suggested by its launch prospectus.

In particular, Woodford got the board to raise the ceiling on the proportion of unquoted companies he could hold (from 60% to 80%) and to drop a policy of not using long-term gearing (£150m borrowing facilities were arranged and utilised).

My other big concern is that some of the unquoted companies are in the books at what could prove to be over-rosy valuations, due to the subjective nature of such valuations.

Discount doesn’t tempt me

Since the gating of Woodford’s flagship Equity Income Fund and his plan to sell its unquoted and  illiquid holdings, many of which are also held by Patient Capital, the latter’s share price has dived to a steep discount to net asset value (NAV) — currently 33%.

The board has recently agreed a schedule with Woodford to halve the level of gearing within six months and to be ungeared within 12 months. Woodford also now has to get board approval for any new investment or further investment in existing assets.

I view this as shutting the stable door after the horse has bolted. Furthermore, I think it’ll only add to the pressure on the valuation — and in some cases survival — of the investee companies. As such, even the 33% discount to NAV doesn’t tempt me.

Patient capital context

Caledonia Investments is a long-established trust. There’s a particular context for its deployment of patient capital: “Our heritage can be traced back to the shipping empire established by Sir Charles Cayzer in 1878. We continue to enjoy the backing of the Cayzer family, who own some 48.5% of the share capital. The Cayzer family shareholding provides both support to our long-term value investment horizon and provides a foundation to our culture of conservative generational wealth management.”

Differentiated portfolio

The trust employs four strategies. In what it calls its Quoted Pool there are “high-quality compounding companies.” Its current 19 core holdings include Microsoft, Nestlé and AG Barr. Well-known listed companies also feature in its Income Pool. These include the likes of Lloyds, GlaxoSmithKline and Imperial Brands.

Its other two pools — Unquoted and Funds — target higher returns. In the Unquoted Pool there are 11 established UK businesses in which Caledonia has a majority or significant minority interest. For example, Cooke is the market-leading UK manufacturer of premium-end cinematography lenses for film and television. Meanwhile, its Funds Pool is focused on US and Asian private equity funds.

I like Caledonia’s differentiated portfolio and deployment of patient capital in the Unquoted Pool. The stock is trading at an attractive 16% discount to NAV. It also offers a 1.9% dividend yield, and has a record of 52 consecutive years of dividend increases.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool’s board of directors. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline and Microsoft. The Motley Fool UK has the following options: long January 2021 $85 calls on Microsoft. The Motley Fool UK has recommended Imperial Brands and Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Is the S&P 500 going to 10,000 by 2030? This expert thinks so

One stock market strategist sees animal spirits taking hold and driving the S&P 500 index even higher by the end…

Read more »

Investing Articles

I’m expecting my Phoenix Group shares to give me a total return of 25% in 2025!

Phoenix Group shares have had a difficult few months but that doesn't worry Harvey Jones. He loves their 10%+ yield…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

14.5bn reasons why I think the Legal & General share price is at least 11% undervalued

According to our writer, the Legal & General share price doesn’t appear to reflect the underlying profitability of the business. 

Read more »

Young black man looking at phone while on the London Overground
Value Shares

After a 16% drop, FTSE 100 stock JD Sports Fashion looks like a steal to me

This FTSE 100 stock has tanked since mid-September. Edward Sheldon believes that there's value on offer after the share price…

Read more »